Does RIBOCICLIB Cause Therapy cessation? 71 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 71 reports of Therapy cessation have been filed in association with RIBOCICLIB (KISQALI). This represents 0.3% of all adverse event reports for RIBOCICLIB.
71
Reports of Therapy cessation with RIBOCICLIB
0.3%
of all RIBOCICLIB reports
0
Deaths
18
Hospitalizations
How Dangerous Is Therapy cessation From RIBOCICLIB?
Of the 71 reports, 18 (25.4%) required hospitalization, and 1 (1.4%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 71 reports have been filed with the FAERS database.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Malignant neoplasm progression (2,468)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which RIBOCICLIB Alternatives Have Lower Therapy cessation Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN